Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dermatological Indications May Drive Humira Growth, Abbott Says

This article was originally published in The Pink Sheet Daily

Executive Summary

An approval for psoriatic arthritis could occur in the second half of 2005; the supplemental BLA has an estimated user fee date in October. First quarter U.S. Humira sales were down from the previous quarter due to competition from Amgen/Wyeth's Enbrel and "disappointing" penetration of the early RA market, Abbott says.

You may also be interested in...

Amgen Expects Enbrel Prefilled Syringes To "Blunt" Humira Competition

The company will launch the new delivery device by the end of November, one month ahead of schedule. Enbrel's growth has been driven by performance in psoriasis, where the product holds the vast majority of market share among biologics.

Amgen Polishes Enbrel Label

The TNF-inhibitor adds first-in-class claim for “major clinical response” in rheumatoid arthritis and gets approval for new once-weekly prefilled syringe. Five-year radiographic data also added to the label.

Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues

“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts